eClinical Solutions Expands Leadership Team to Accelerate Company’s Rapid Growth Amidst Life Science Industry’s Digital Transformation

2022-06-15 16:27:27 By : Ms. Cindy Gu

Venu Mallarapu named Vice President of Global Strategy and Operations, will help scale the global adoption, market expansion and innovation of eClinical’s modern clinical trial software and services

BOSTON, June 15, 2022--(BUSINESS WIRE)--eClinical Solutions, a global provider of digital clinical software and services, today announced the appointment of Venu Mallarapu as the company’s Vice President of Global Strategy and Operations, a new role for the organization. Mallarapu has over two decades of experience in business and IT advisory, strategic consulting, and relationship and delivery management to global life sciences research and development (R&D) organizations. He will build on the company’s existing platform and service offerings and collaborate with the leadership team, to lead the next phase of eClinical Solutions’ strategic development, as demand for clinical trial technology increases both in the U.S. and internationally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005723/en/

Venu Mallarapu, Vice President of Global Strategy and Operations, eClinical Solutions (Photo: Business Wire)

According to Grand View Research, the rising prevalence of chronic disease and a growing clinical trials market in developing countries is driving a projected annual compound growth rate (CAGR) of 5.1% through 2027 in the global clinical trial market. Concurrently, VynZ Research predicts eClinical platforms for clinical trials will witness a 14% CAGR between 2020-2025. In a 2022 report by Gartner® titled "Market Guide for Life Science E-Clinical Platforms," authored by Jeff Smith, Sr. Director Analyst states, "Gartner expects that e-clinical platforms will continue to play a central role in [life science] development organizations." He continued, "The e-clinical platform provides an opportunity for IT leaders to rethink traditional solution boundaries, optimize trial processes by leveraging prebuilt integrations between various product types and build a platform that is greater than the sum of its parts."

eClinical Solutions’ elluminate Clinical Data Cloud, the foundation for digital trials, provides a central location for all clinical and operational data, creating a single source of truth across all data sources from ingestion to insights. The platform’s out of the box data connectors, built-in automation, advanced analytics, and self-service access to data from a single location allows value to be recognized faster and enables smarter decision making through the trial lifecycle for top 20, mid-size, and emerging life science companies.

"As the E-clinical platform market grows, we are focused on continuing to stay ahead of the curve and providing life science companies with the most modern clinical trial technology and service capabilities that will drive significant operational efficiencies and meaningful financial results," said Raj Indupuri, CEO and Co-founder, eClinical Solutions. "We are excited to welcome Venu to our leadership team to accelerate adoption across market segments and help us further our position as global leaders in the industry. His expertise as a leader in digital transformation in life sciences and building global teams at scale that deliver value and growth make him an invaluable addition to our company."

Among his various responsibilities, Venu will collaborate with the product and engineering teams and provide input into the vision, strategy, and roadmap for the elluminate Clinical Data Cloud. He will also further establish a collaboration framework across onsite and offshore delivery teams and support key strategic partnerships that drive product and services growth.

"The life science industry, and clinical development ecosystem, have tremendous opportunities to innovate, digitize and transform itself. I’m excited about eClinical’s mission of bringing innovative technologies and services to clinical development teams that result in new therapies being available to patients faster," said Mallarapu. "I’m honored to join eClinical Solutions and help our current and future clients gain even greater value from elluminate and eClinical Data Services by enhancing our first-in-class solutions and services to address evolving industry changes, needs, and expectations."

Mallarapu joins eClinical Solutions from Cognizant Technology Solutions, a multinational IT services and consulting company, where he served as Senior Director and Global Head of R&D Solutions Group, managing strategic partnerships with platforms vendors. Prior to that role, he served as Director of Technology & Alliances for Navitas Life Sciences (formerly TAKE Solutions, Inc.), a full-service clinical trial contract research organization (CRO), where he was responsible for developing business solutions for R&D, as well as managing and building new strategic partnerships.

To hear more about the opportunities Venu will be focused on at eClinical, listen to this conversation hosted by eClinical CEO Raj Indupuri, and to learn more about the industry experts and innovators that comprise the eClinical Solutions’ leadership team, please visit: https://www.eclinicalsol.com/about/leadership/.

Gartner is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

eClinical Solutions helps life sciences organizations around the world accelerate clinical development initiatives with expert data services and the elluminate Clinical Data Cloud – the foundation of digital trials. Together, the elluminate platform and digital data services give clients self-service access to all their data from one centralized location plus advanced analytics that help them make smarter, faster business decisions. Find out more at eclinicalsol.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005723/en/

Alex Connelly eClinical@pancomm.com (401) 486-7437

In this article, we discuss the 10 stocks that Jim Cramer recommends selling. If you want to read about some more stocks that Jim Cramer recommends selling, go directly to Jim Cramer Recommends Selling These 5 Stocks. A lot of growth investors are reeling from the aftershocks of the incredible crash in crypto markets over […]

(Bloomberg) -- DoubleLine Capital Chief Executive Officer Jeffrey Gundlach said the Federal Reserve should raise its target interest rate to 3% on Wednesday, calling for a hike that would be dramatically larger than what most forecasters are predicting.Most Read from BloombergAmericans Are Building Vacation-Home Empires With Easy-Money LoansChina Alarms US With Private Warnings to Avoid Taiwan StraitVolatility Grips Stocks as Treasury Yields Surge: Markets WrapBiden’s ‘Never Been More Optimistic

When Elon Musk, the CEO of Tesla , speaks about the environment and the problems facing the automobile sector, industry actors listen. For many years, the billionaire worked hard to convince his peers, authorities and consumers that electric vehicles were the future. The tech tycoon has twice recounted these difficulties this year, in March to defend competitor Rivian and in April during a Ted Talk.

Yahoo Finance's Akiko Fujita breaks down how stocks, bonds, and sectors are performing in midday trading.

This company has raised its payout for 52 years straight and at the current share price offers a market-trouncing 7.6% yield.

Yahoo Finance Live looks at several of today's trending stocks tied to leading industry stories, including billionaire Harold Hamm's offer to take his company Continental Resources private.

In this piece we will take a look at the nine shipping stocks that pay dividends. If you want to skip our primer on the shipping industry, the attractiveness of dividends, and want to take a look at the top five stocks in this piece, then head on over to 5 Best Shipping Stocks That […]

"Demand for airplanes is as robust as I've ever seen it,' Boeing CEO Dave Calhoun said earlier this week.

Analysts reserved their concerns over the prospects for Adobe Inc (NASDAQ: ADBE) amid current macro uncertainty ahead of its Q2 results. RBC Capital analyst Matthew Hedberg maintained Adobe with an Outperform and cut the price target from $600 to $500. An improved start to the year after a mixed Q4 led to the enhanced sentiment. However, it has now given way to many macro concerns. Hedberg remained concerned over the durability of customer spending and the resiliency, particularly of digital med

The S&P 500 plunged into a bear market earlier this week for the first time since March 2020, sending many investors into a tizzy. This could present a buying opportunity, however.

Inflation is on everyone’s minds these days, and for good reason. Annualized price increases are at their highest level in 41 years, and are evoking memories of the Carter Administration. Carter’s failed attempts to curb inflation killed his chances in the 1980 election, and Reagan’s Administration only beat inflation at the cost of double-digit interest rates. With an election coming up, an Administration flailing, and the Federal Reserve on course this week to bump up rates again, the parallel

When Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett buys a stock, Wall Street and investors wisely pay close attention. Since taking the reins as CEO in 1965, Buffett has overseen the creation of more than $645 billion in value for shareholders, as well as delivered an aggregate return on the company's Class A shares (BRK.A) of 3,641,613%. Aside from Berkshire Hathaway's annual shareholder meeting and the letter Buffett writes to shareholders each year, the most-anticipated event is the company's quarterly 13F filing with the Securities and Exchange Commission (SEC).

Yahoo Finance's Julie Hyman discusses how stocks are trading in anticipation of the Fed's decision on Wednesday.

Yahoo Finance Live anchors discuss the move in MicroStrategy stock after CEO Michael Saylor announced the company hasn't received a margin call on its bitcoin loan as the crypto falls below $21,000, plus Roblox shares rise after the company reported lower bookings.

Billionaire Michael Saylor and his company MicroStrategy are at the center of attention with the fall of Bitcoin. Before we even look at the numbers, it's safe to say that Saylor and MicroStrategy are among the biggest losers in Bitcoin's return to earth as they adopted a cryptocurrency investment strategy in 2020. MicroStrategy holds 129,218 bitcoins, 4,827 of which were purchased in the first quarter at an average price of $44,645.

Roku (NASDAQ: ROKU) has been capturing headlines lately due to rumors that Netflix (NASDAQ: NFLX) may be interested in acquiring the company. Roku gives users access to their streaming services through its platform, and its market capitalization has fallen more than $50 billion from its high. Note, however, that this is only speculation as neither Roku nor Netflix have substantiated the news.

These highly profitable stocks are valued at just three to six times Wall Street's forecast earnings for 2023.

In this article, we discuss the top 10 dividend stocks to buy according to Peter S. Stamos’ Stamos Capital. You can skip our detailed analysis of Stamos’ past life and his hedge fund history, and go directly to read Top 5 Dividend Stocks to Buy According to Peter S. Stamos’ Stamos Capital. Peter S. Stamos […]

Stifel Chief Economist Lindsey Piegza joins Yahoo Finance Live to discuss market expectations ahead of the Fed's FOMC meeting, inflation, and recessionary risks.

Buffett swapped out Wells Fargo and Goldman Sachs for a beaten-down bank.